Standout Papers

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib:... 2012 2026 2016 2021 417
  1. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial (2012)
    Jeffrey R. Infante, Leslie A. Fecher et al. The Lancet Oncology

Immediate Impact

1 by Nobel laureates 17 from Science/Nature 69 standout
Sub-graph 1 of 22

Citing Papers

Deuterium in drug discovery: progress, opportunities and challenges
2023 Standout
Hallmarks of aging: An expanding universe
2023 Standout
1 intermediate paper

Works of Donna S. Cox being referenced

Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect
2020
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
2012 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Donna S. Cox 857 729 112 278 54 2.2k
Val R. Adams 529 563 51 174 61 1.7k
Jürgen Venitz 1093 594 132 149 87 2.8k
John F. Martin 867 255 18 158 46 2.6k
John F. Parkinson 802 153 32 129 54 2.9k
F. J. Cleton 563 1092 119 80 63 2.7k
Philip T. Leese 897 946 105 65 51 2.5k
Simon Zhou 715 485 75 113 70 2.3k
Andreas H. Wagner 743 251 38 77 97 2.8k
Lili Fu 1446 161 118 160 85 3.1k
Luca Puccetti 768 141 9 527 80 1.9k

All Works

Loading papers...

Rankless by CCL
2026